ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Zenas BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$26.71+1.87 (+7.53%)
Close on Oct 19, 2026
- Market cap
- $1.69B
- P/E (TTM)
- –
- Dividend yield
- –
Zenas BioPharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Market Cap | $1.74B | $164.85M |
| Enterprise Value | $1.29B | $87.06M |
| PB Ratio | 7.05 | 2.03 |
| P/TBV Ratio | 7.05 | 2.31 |
Income (trailing twelve months)
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Operating Income | -$475.57M | -$21.44M |
| Pretax Income | -$484.16M | -$14.45M |
| Net Income | -$484.38M | -$22.46M |
| EBITDA | -$475.57M | -$16.91M |
| EPS (Diluted) | -$8.98 | -$0.83 |
Returns
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -199.0% | -53.1% |
| Return on Assets (ROA) | -97.4% | -41.0% |
| Return on Capital Employed (ROCE) | -74.8% | -37.8% |
Balance sheet
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $673.90M | $62.42M |
| Total Debt | $222.96M | $120.13M |
| Net Cash (Debt) | $450.94M | $15.68M |
| Net Cash Per Share | $6.92 | $0.66 |
| Equity (Book Value) | $247.10M | $48.79M |
| Book Value Per Share | $3.79 | $1.36 |
| Tangible Book Value | $247.10M | $23.06M |
| Working Capital | $587.98M | $75.77M |
Financial position
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Current Ratio | 9.93 | 3.30 |
| Quick Ratio | 10.24 | 2.39 |
| Debt / Equity | 0.90 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$225.97M | -$12.35M |
| Capital Expenditures | -$2.00K | -$1.06M |
| Free Cash Flow | -$225.97M | -$20.28M |
| FCF Per Share | -$3.47 | -$0.42 |
Efficiency
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Profits Per Employee | -$2.90M | -$703.34K |
| Employee Count | 167 | 74 |
Dividends and yields
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Earnings Yield | -27.8% | -22.7% |
| FCF Yield | -13.0% | -9.07% |
Shares
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Shares Outstanding | 65,176,700 | 58,179,650 |
| Shares Change (QoQ) | 1.52% | 0.54% |
| Float | 41,642,000 | 49,173,100 |
| Shares Held by Insiders | 36.1% | 11.6% |
| Shares Held by Institutions | 94.0% | 59.4% |
Scores
| Measure | Zenas BioPharma | Industry median |
|---|---|---|
| Altman Z-Score | -0.84 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Zenas BioPharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.